Affiliate disclosure: The RX Index earns a commission when you sign up with some of the providers mentioned on this page. It does not affect what you pay, and it never determines our rankings or which providers we cover. Read the full disclosure.
Best GLP-1 for Cardiovascular Protection in 2026
By The RX Index Editorial Team · Last verified:
The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers.
Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.
It never changes which medicine the evidence supports — on this page, the science picks the winner, not the payout.This guide is for learning. It does not replace your doctor or cardiologist.
The best GLP-1 for cardiovascular protection is Wegovy (semaglutide) — for most adults who already have heart disease plus overweight or obesity. It’s the only weight-loss GLP-1 the FDA has approved to lower the risk of cardiovascular death, heart attack, and stroke in that group. In its main heart study, called SELECT, those events happened to 6.5% of people on Wegovy versus 8.0% on a placebo — about a 20% lower risk. (SELECT studied people who did not have diabetes.)
But here’s the part that surprises almost everyone: the GLP-1 that takes off the most weight — Zepbound — is not the one with proven heart protection. More weight loss does not automatically mean a healthier heart on paper. We’ll show you exactly why, and when it should change your choice.
Your situation also matters. If you have type 2 diabetes, the stronger play might be Ozempic, oral semaglutide, Trulicity, or Victoza. If you’re eyeing a cheaper compounded version to get the same heart benefit — that benefit hasn’t been demonstrated for compounded products, and we won’t pretend it has.
Best GLP-1 for cardiovascular protection, by your situation
| Your situation | Your heart pick | Why | Your next step |
|---|---|---|---|
| You already have heart disease (past heart attack, stroke, stent, bypass, or clogged arteries) plus overweight or obesity | Wegovy | The only weight-loss GLP-1 FDA-approved to reduce cardiovascular death, heart attack, and stroke in adults with established heart disease and overweight or obesity | Check Wegovy eligibility and coverage with Ro (sponsored affiliate link, opens in a new tab) |
| You have type 2 diabetes + heart disease | Ozempic (or oral semaglutide) | These carry FDA heart-protection approvals for people with diabetes | See our Best GLP-1 for Diabetes guide — it’s built for you |
| You want a pill, heart protection is the goal, no diabetes | Wegovy pill | Carries the same FDA heart approval as the shot | Check the Wegovy pill on Ro (sponsored affiliate link, opens in a new tab) or Sesame (sponsored affiliate link, opens in a new tab) |
| Maximum weight loss is your #1 goal | Zepbound | Usually more weight loss than Wegovy — but no FDA heart-protection approval yet | See our Best GLP-1 for Weight Loss guide |
| You’re on Medicare with heart disease + extra weight | Wegovy | Medicare can cover it for the heart reason (not for weight loss alone) | Read the coverage section below |
| You’re thinking about a compounded version for your heart | Don’t count on it | Compounded GLP-1s aren’t FDA-approved and have no heart-outcome data | Check the brand-name path or take the quiz |
The one-line rule:
If your goal is protecting your heart, start with the medicine the FDA actually approved for that job — then pick how you get it. Don’t pick a provider first and reverse-engineer the reason later.
Have heart disease and carry extra weight?
Wegovy is the GLP-1 with the proven heart data for your group — and you don’t need to wonder if you “qualify” on your own.
Check your eligibility and coverage for FDA-approved Wegovy with Ro → (sponsored affiliate link, opens in a new tab)(sponsored) · Ro runs a free coverage check and handles the insurance paperwork.
Which GLP-1 is FDA-approved for cardiovascular protection?
Wegovy (semaglutide) is the only weight-loss GLP-1 with an FDA approval to reduce cardiovascular death, heart attack, and stroke — in adults who have heart disease plus overweight or obesity. Several diabetes GLP-1s (Ozempic, oral semaglutide, Trulicity, Victoza) also carry heart-protection approvals, but those are for people with type 2 diabetes. Tirzepatide (Zepbound and Mounjaro) does not have a heart-protection approval yet.
What is MACE?
MACE is doctor shorthand for “major adverse cardiovascular events” — cardiovascular death, a non-fatal heart attack, or a non-fatal stroke, grouped together. When a drug “reduces MACE,” fewer of those three happened.
What is established cardiovascular disease?
Established ASCVD means you already have heart or artery disease — a past heart attack, a past stroke, a stent or bypass, or arteries narrowed by plaque.
The cardiovascular evidence matrix
Every GLP-1 people compare for the heart, what’s actually approved, and the proof behind it — built from FDA approvals and published trials. We re-check the moving parts monthly.
| Medication | Who it’s the heart pick for | FDA-approved to cut heart-attack / stroke risk? | The proof | What NOT to assume |
|---|---|---|---|---|
| Wegovy (semaglutide shot, 1.7/2.4 mg) | Heart disease + overweight or obesity | Yes | SELECT trial, 17,604 adults: MACE in 6.5% on Wegovy vs 8.0% on placebo; HR 0.80 (95% CI, 0.72–0.90) — about a 20% lower risk. | Approved for people who already have heart disease — not as general “heart insurance” for everyone. |
| Wegovy pill (oral semaglutide, 25 mg) | Same group, but you want a pill | Yes — same approval on the label | Cardiovascular approval carries over from the shot; outcomes trial (SELECT) was run with the shot. Approved Dec 2025. | Confirm your provider stocks it — it’s new. |
| Ozempic (semaglutide shot) | Type 2 diabetes + heart disease | Yes | SUSTAIN-6: ~26% lower MACE risk (HR 0.74; 95% CI, 0.58–0.95). Also FDA-approved to protect kidneys in type 2 diabetes with CKD. | Approved for diabetes, not weight loss. Its approval isn’t identical to Wegovy’s. |
| Oral semaglutide (Rybelsus / Ozempic tablets) | Type 2 diabetes at high heart risk — even without a past event | Yes | SOUL trial, 9,650 adults: ~14% lower MACE risk (HR 0.86; 95% CI, 0.77–0.96). | Strict dosing rules; it’s a diabetes drug, not a swap-in “Wegovy pill” for weight loss. |
| Trulicity (dulaglutide shot) | Type 2 diabetes with heart disease or several risk factors | Yes | REWIND trial: approved to reduce MACE in adults with type 2 diabetes who have established heart disease or multiple heart-risk factors. | It’s a diabetes/heart drug, not a top weight-loss pick. |
| Victoza (liraglutide shot) | Type 2 diabetes + heart disease | Yes | LEADER trial: ~13% lower MACE risk. | Daily shot; less convenient than weekly options. |
| Zepbound (tirzepatide shot) | Weight loss / sleep apnea — not the heart-approval lane | No (as of May 2026) | Usually more weight loss than Wegovy, and risk modeling predicts a bigger drop in future heart risk — but that’s a prediction based on weight loss, not proven heart-event data. Its big heart-outcomes trial (SURMOUNT-MMO) hasn’t reported. | Don’t assume Zepbound protects your heart the way Wegovy is approved to. |
| Mounjaro (tirzepatide shot) | Type 2 diabetes — not the heart-approval lane | No (as of May 2026) | In SURPASS-CVOT, Mounjaro worked about as well as Trulicity at preventing major heart events in type 2 diabetes, but still has no FDA heart-protection approval. | Promising, not approved for the heart. |
| Foundayo (orforglipron pill) | Weight management | No | Newer once-daily pill approved for weight management in 2026. No FDA heart-protection approval; no cardiovascular outcomes trial reported. | Don’t pick it for heart protection — the evidence isn’t there. |
| Saxenda (liraglutide 3.0 mg shot) | Weight management | No (at the weight-loss dose) | LEADER heart data belongs to liraglutide’s diabetes dose (Victoza), not Saxenda’s weight-loss dose. | Don’t borrow Victoza’s heart data for Saxenda. |
| Compounded semaglutide / tirzepatide | Not a heart-protection choice | No | Not FDA-approved; not reviewed for safety, effectiveness, or quality. No compounded GLP-1 carries an FDA-approved cardiovascular indication; outcomes trials were not run on compounded preparations. | Brand-name proof does not transfer to a compounded preparation. |
Sources: SELECT (NEJM, 2023); SUSTAIN-6; SOUL; REWIND; LEADER; SURPASS-CVOT; FDA approvals. Re-verified May 29, 2026.
How much do these drugs actually lower heart-attack and stroke risk?
In real numbers: Wegovy lowered major heart events by about 20% in people with heart disease and extra weight. In diabetes trials, Ozempic lowered them about 26% (SUSTAIN-6) and oral semaglutide about 14% (SOUL). Those are drops in actual events — heart attacks, strokes, and heart-related deaths — not just pounds lost. One caution: those percentages come from separate trials in different groups, so they aren’t a head-to-head ranking.
The headline study for Wegovy is SELECT. It followed 17,604 adults for about three and a half years. Everyone already had heart disease and was overweight or obese, but none had diabetes. Half got Wegovy on top of their usual heart care; half got a placebo. Fewer people on Wegovy had a heart attack, stroke, or died from heart disease — and the benefit showed up across ages, body sizes, and both sexes.
An honest detail most pages skip:
The clear win was the overall drop in major heart events (the 20% figure). When researchers looked at heart-related deaths on their own, the drop pointed the right way (about 15%, HR 0.85) but did not reach statistical significance in the trial’s formal testing. So the proven benefit is “fewer major heart events,” not a standalone promise about deaths. We’d rather you have the precise version.
What does a 20% drop mean for one real person?
It’s a relative drop, so the real-world size depends on your starting risk. In SELECT, the absolute difference was 1.5 percentage points (8.0% down to 6.5%). Put another way: roughly 67 people took Wegovy for the length of the study to prevent one major heart event that would otherwise have happened. If your personal risk is higher — say you’ve already had a heart attack — the benefit for you tends to be larger. Your cardiologist can put a real number on your situation.
Want to see whether your plan treats Wegovy differently because of the heart approval?
Run Ro’s free GLP-1 Insurance Coverage Checker before you pay a dollar out of pocket → (sponsored affiliate link, opens in a new tab)(sponsored)
Why Wegovy is the top pick if you have heart disease and extra weight
For the most common version of this search — heart disease plus overweight or obesity — Wegovy is the clear answer because it’s the one medicine in this class the FDA approved for that group, backed by the SELECT trial. It’s used alongside a lower-calorie diet and more activity, and it works on top of your standard heart medicines, not instead of them.
Who this is for:
- You’ve had a heart attack, stroke, stent, bypass, or you’ve been told you have clogged arteries (ASCVD).
- You’re overweight or obese (BMI of 27 or higher).
- You want a medicine with proof it lowers heart events — not just weight.
Who this is not automatically for:
- People with no diagnosed heart disease who want a “heart-healthy” reason to lose weight.
- People who want a compounded version and assume it carries the same heart proof. It doesn’t.
- People who just had an unstable cardiac event — timing is a cardiologist’s call.
If you want the deep dive on who qualifies, the exact criteria, and the cost, we keep a full breakdown in our Wegovy for Heart Disease guide. This page is the hub; that’s the Wegovy branch.
Wegovy vs Zepbound for your heart: why the bigger weight loss isn’t the winner
For heart protection, Wegovy is the stronger answer right now. Zepbound (tirzepatide) usually causes more weight loss and even looks better in risk-calculator predictions — but it has no FDA heart-protection approval and no finished heart-outcomes trial in this setting. Wegovy is the one a heart study actually showed lowers heart attacks and strokes.
Wegovy does NOT produce the most weight loss — Zepbound usually does. If pure weight loss is your number-one priority, Zepbound is the stronger choice. But because your goal here is protecting your heart, Wegovy wins — it’s the medicine a cardiovascular trial actually tested and showed reduced heart events, while Zepbound skips that and gives you the bigger number on the scale. You’re not choosing the bigger weight number. You’re choosing the one that actually lowered major heart events in the people who were studied.
| Question | Wegovy | Zepbound |
|---|---|---|
| FDA-approved to reduce major heart events? | Yes | No (not yet) |
| Weight-loss strength | Strong | Usually stronger |
| Best fit for | Heart protection | Maximum weight loss / sleep apnea |
| Risk of choosing it for the wrong reason | Paying for weight-loss strength when proven heart benefit was the real goal | Assuming more weight loss equals proven heart-event reduction |
Two things make this make sense:
- Weight loss is a stand-in. Proven events are the goal. A drug can be great for weight and still not have shown it prevents heart attacks. Zepbound’s modeling looks strong, but modeling is a prediction. SELECT measured the real thing.
- The proof for Zepbound is coming, not here. Its big heart trial in people with obesity (SURMOUNT-MMO) hasn’t reported. A study in people with heart failure plus obesity (SUMMIT) was encouraging, but Zepbound still isn’t FDA-approved for heart failure or for cutting heart-attack and stroke risk. We’ll update this page the day that changes.
If heart protection is the reason you’re here, start with the proven option.
See if FDA-approved Wegovy is right for you on Ro → (sponsored affiliate link, opens in a new tab)(sponsored)
Wegovy vs Ozempic: which is right for you?
Wegovy and Ozempic are both semaglutide, but they’re not the same decision. Wegovy is the cleaner answer if you have heart disease plus extra weight. Ozempic is the cleaner answer if you have type 2 diabetes and heart disease.
Same medicine family, two different approved jobs:
Ask about Wegovy if:
Your situation is heart disease + overweight or obesity, and your goal is heart protection tied to weight treatment.
Ask about Ozempic if:
You have type 2 diabetes and heart disease. Its heart approval — and its kidney-protection approval — live in the diabetes world.
Don’t choose between them based on which name you’ve heard more. Choose based on whether diabetes is part of your picture. Genuinely unsure? The quiz at the bottom sorts it in about a minute.
Have type 2 diabetes? Here’s your stronger heart play
If you have type 2 diabetes, the best GLP-1 for cardiovascular protection may not be Wegovy first. Ozempic, oral semaglutide, Trulicity, and Victoza all carry FDA heart-protection approvals for people with diabetes. Your best fit depends on whether you also have established heart disease, kidney disease, and whether you want a shot or a pill.
| Medication | Heart-approval group | Form | Quick note |
|---|---|---|---|
| Ozempic | Type 2 diabetes + heart disease | Weekly shot | Strong diabetes + heart fit; also kidney protection |
| Oral semaglutide (Rybelsus / Ozempic tablets) | Type 2 diabetes at high heart risk | Daily pill | Pill option; strict empty-stomach dosing |
| Trulicity | Type 2 diabetes + heart disease or risk factors | Weekly shot | Broad diabetes heart approval |
| Victoza | Type 2 diabetes + heart disease | Daily shot | Proven, less convenient (daily) |
Because your decision runs through your diabetes care, we put the full comparison — A1C, heart, kidney, and 2026 prices — in our Best GLP-1 for Diabetes guide. Start there. It’s written for you, not for the weight-loss crowd.
Want a pill? What’s proven for your heart and what isn’t
Not all GLP-1 pills are equal for the heart. The Wegovy pill carries the same heart approval as the Wegovy shot. Oral semaglutide for diabetes (Rybelsus, now also sold as Ozempic tablets) carries a heart approval for high-risk type 2 diabetes. Foundayo is a weight pill with no heart-outcome data yet — so it shouldn’t be your pick for heart protection.
Wegovy pill (oral semaglutide)
Approved December 2025, and its label includes the cardiovascular approval. If needles are your dealbreaker, this is a real way to get the proven heart option. The big outcomes trial used the shot, so the strongest data sits there — but the FDA extended the approval to the pill.
Oral semaglutide for diabetes (Rybelsus / Ozempic tablets)
The heart approval here is for type 2 diabetes, not weight loss. Same molecule as the Wegovy pill, different dose and different approved use.
Foundayo (orforglipron)
A newer once-daily pill approved for weight management in 2026. No heart-outcome studies. Don’t lead with it for heart protection unless the FDA adds that approval later.
Should you use a compounded GLP-1 for heart protection?
The SELECT result — that 20% drop in heart events — belongs to the specific FDA-approved Wegovy product that was tested. We don’t stretch that proof onto a compounded preparation.
Claims we will not make about compounded GLP-1s:
- That they are generic versions of, or the same as, FDA-approved Wegovy, Ozempic, or Zepbound.
- That they use the same active ingredient as the FDA-approved drugs.
- That they’re clinically proven to produce the same results.
- That the cardiovascular evidence above applies to them.
If cost is the reason compounded looked appealing, read the next two sections first. There’s a real chance the proven, brand-name option costs less than you think — especially with the heart approval in play. If brand-name still doesn’t fit, our GLP-1 cost guide lays out every route honestly, so you can decide with full information.
Will Medicare or insurance cover a GLP-1 for heart protection?
This is where the heart approval quietly changes the math. Medicare’s drug plans (Part D) are banned by law from covering GLP-1s for weight loss. But because Wegovy has a cardiovascular approval, Part D plans can cover it when it’s prescribed to lower heart risk in adults with heart disease and excess weight. State Medicaid programs are required to cover it for that heart use. Commercial plans often cover it too, usually with prior approval.
Medicare (Part D)
If your only reason were weight loss, Medicare would say no. But “reduce heart-attack and stroke risk in someone with heart disease and obesity” is a covered medical reason, so Wegovy can be a covered Part D drug for the heart use. You usually need prior authorization. The separate Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027) is a weight-management demonstration with its own rules — the cardiovascular coverage path for Wegovy runs through standard Part D and doesn’t depend on that program.
Commercial insurance
Many plans cover Wegovy with prior authorization. With coverage plus the Wegovy Savings Offer, eligible commercially insured patients can pay as little as $25 a month (NovoCare lists a maximum savings of $100 a month). A heart-disease diagnosis can strengthen the case, since it’s a covered medical use rather than weight loss alone.
Documentation that helps your approval:
- A clear heart-disease diagnosis (past heart attack, stroke, PAD, or ASCVD)
- Your weight / BMI
- Your current medicines
- The prior-authorization form your plan requires
- A letter of medical necessity if you get denied — ask Ro’s care team or your cardiologist to help draft one
Not sure how your plan handles it?
Check your Wegovy coverage with Ro → (sponsored affiliate link, opens in a new tab)(sponsored) · Ro’s team runs a free check and handles the prior-authorization paperwork for you.
What it costs right now
Your cost depends on whether you use insurance, Medicare, or pay cash. With insurance and a savings card, the proven option can run about $25 a month. Paying cash, the Wegovy pill starts around $149 a month and the shot around $199 a month for the first couple of fills (figures verified ).
| Price claim | Source | Verified | The fine print |
|---|---|---|---|
| Commercially insured: as little as $25/month (max savings $100/month) | NovoCare / Wegovy.com | Requires commercial coverage for Wegovy + the Wegovy Savings Offer | |
| Self-pay Wegovy pill: from $149/month (1.5 mg & 4 mg); 9 mg & 25 mg about $299/month | NovoCare | The 4 mg $149 price runs through Aug 31, 2026, then $199/month | |
| Self-pay Wegovy pen: $199/month for the first two fills, then $349/month | Wegovy.com | $199 intro applies to 0.25 mg & 0.5 mg through June 30, 2026 | |
| Ro Body (sponsored affiliate link, opens in a new tab) membership: $39 first month, then as low as $74/month (annual, paid upfront) or $149/month monthly | Ro | Membership is the care/support; medication cost is separate | |
| Success by Sesame: from $59/month (annual plan) or $99/month month-to-month | Sesame | Membership only; medication cost is separate | |
| Costco members (via Sesame): Wegovy or Ozempic injections about $349/month; Wegovy pill from $149/month | Sesame | Self-pay at Costco Pharmacy; about 50% off standard retail |
Ro — best if you want the insurance-aware path
Ro carries FDA-approved Wegovy (shot and pill), runs a free GLP-1 Insurance Coverage Checker, and has a team that handles prior-authorization paperwork. Honest note: Ro isn’t automatically the cheapest, because the membership is separate from the medicine. Read the membership screen before you pay.
Sesame (with Costco) — best if you’re paying cash
Sesame lists one of the broadest brand-name menus around (Wegovy, Ozempic, Zepbound, and more), lets you pick your own provider, and helps with prior-authorization paperwork. Costco members get the strongest cash prices on Wegovy and Ozempic injections.
Before you pay cash, make sure you’re not leaving coverage on the table. For the full 2026 cost breakdown including savings card rules, see our best GLP-1 with active savings card guide.
Which GLP-1 is best after a heart attack?
For someone with a prior heart attack plus overweight or obesity, Wegovy is the strongest evidence match when the goal is reducing future heart events — that’s the population the SELECT trial studied. But when to start after a recent heart attack should be decided with your cardiologist, because recent unstable symptoms, medication changes, and cardiac recovery can change the safest start date.
This is one place to slow down and loop in your care team rather than start on your own. A GLP-1 can be part of the plan after a cardiac event — but it works alongside the rest of your recovery (your other heart medicines, cardiac rehab, follow-up visits), not in place of it. Once your cardiologist gives the green light, a telehealth provider can be a fast, low-friction way to get the prescription and coverage sorted.
Who should be careful — or wait
GLP-1s are prescription medicines, not supplements. Some people shouldn’t start without a closer look. Talk with your doctor first if any of these apply to you.
Don’t start (hard stops on the label):
- A personal or family history of medullary thyroid cancer, or the condition MEN2.
- A serious allergic reaction to the specific medicine before.
Use caution and get medical guidance if you have:
- A history of pancreatitis or gallbladder disease.
- Type 2 diabetes treated with insulin or a sulfonylurea — your doses may need adjusting.
- Kidney concerns — dehydration from nausea can stress the kidneys.
- A recent heart attack or stroke, unstable symptoms, or complex heart failure.
What people say about getting started
Experiences with a telehealth provider speak to the service — the sign-up, the support, the communication — not to weight loss or heart results, and your results may differ. Both Ro and Sesame keep public review profiles (Trustpilot is a good place to read real, recent ones before you commit).
We’ll share the honest side too. A common gripe in Ro reviews is confusion about the billing — the $39 first-month price versus the higher ongoing price. That’s exactly why we said it plainly above: read the membership screen before you pay, so the second charge is never a surprise. Read more in our Ro Body reviews guide.
Best GLP-1 for cardiovascular protection: FAQ
Which GLP-1 is FDA-approved for cardiovascular protection?
Wegovy (semaglutide) is the only weight-loss GLP-1 the FDA has approved to lower the risk of cardiovascular death, heart attack, and stroke in adults who have established cardiovascular disease plus overweight or obesity. Among diabetes medicines, Ozempic, oral semaglutide (Rybelsus and Ozempic tablets), Trulicity, and Victoza also carry cardiovascular indications.
Does Wegovy really lower heart-attack and stroke risk?
Yes. In the SELECT trial of 17,604 adults with cardiovascular disease and overweight or obesity, major adverse cardiovascular events occurred in 6.5% of people on Wegovy versus 8.0% on placebo — a hazard ratio of 0.80 (about a 20% lower risk). The reduction in cardiovascular death on its own did not reach statistical significance, so the demonstrated benefit is fewer major cardiovascular events overall.
Is Wegovy or Ozempic better for the heart?
It depends on diabetes. Wegovy is the better match for adults with established cardiovascular disease plus overweight or obesity. Ozempic is the better match for adults with type 2 diabetes and cardiovascular disease, where its cardiovascular approval applies.
Does Zepbound protect your heart like Wegovy?
Not in a proven, approved way yet. Zepbound (tirzepatide) usually produces more weight loss and shows promising data, but it has no FDA cardiovascular approval and its main cardiovascular-outcomes trial in obesity has not reported. Wegovy is the option with demonstrated cardiovascular-event reduction today.
Which GLP-1 is best after a heart attack?
For someone with a prior heart attack plus overweight or obesity, Wegovy is the strongest evidence match based on the SELECT trial. When to start after a recent heart attack should be decided with a cardiologist, because recent symptoms, medication changes, and recovery can affect the safest start date.
Are compounded GLP-1s proven to protect the heart?
No. Compounded semaglutide and tirzepatide are not FDA-approved, carry no cardiovascular indication, and the cardiovascular-outcomes trials were not run on compounded preparations. The cardiovascular evidence belongs to the specific FDA-approved brand-name products.
Will Medicare cover Wegovy for heart disease?
It can. Medicare does not cover GLP-1s for weight loss alone, but Wegovy’s cardiovascular approval lets Part D plans cover it for the cardiovascular use in adults with established heart disease and overweight or obesity, usually with prior authorization. The 2026 Medicare GLP-1 Bridge is a separate weight-management demonstration with its own rules.
What is MACE?
MACE stands for major adverse cardiovascular events. It usually means a combined measure of cardiovascular death, non-fatal heart attack, and non-fatal stroke. Wegovy’s cardiovascular approval is based on reducing that combined risk.
Is oral semaglutide good for the heart?
It can be. Oral semaglutide for diabetes (Rybelsus, now also sold as Ozempic tablets) has a cardiovascular approval for high-risk type 2 diabetes, and the Wegovy pill carries the cardiovascular approval for the heart-disease-plus-excess-weight group. The approval depends on the specific product and the diagnosis.
Can you take a GLP-1 if you have heart disease?
Often yes. Wegovy’s cardiovascular approval exists specifically for people with established heart disease and overweight or obesity. The main cautions involve recent unstable events, complex heart failure, and interactions with other medicines, which is why a cardiologist should be part of the decision.
Still not sure which GLP-1 program is right for you?
Answer a few quick questions and get your personalized action plan — the medication lane that fits your diagnosis, your coverage path, and the exact questions to bring to your doctor.
Take the free 60-second GLP-1 matching quiz →Sources
- FDA — FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight (Wegovy cardiovascular approval, March 2024).
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). New England Journal of Medicine, 2023 (MACE HR 0.80, 95% CI 0.72–0.90; cardiovascular death HR 0.85, 95% CI 0.71–1.01, not statistically significant).
- Novo Nordisk — FDA approves Novo Nordisk’s Wegovy pill, the first and only oral GLP-1 for weight loss in adults (including the cardiovascular indication, December 2025).
- FDA / Novo Nordisk — Ozempic cardiovascular approval (SUSTAIN-6; MACE HR 0.74, 95% CI 0.58–0.95) and chronic-kidney-disease indication.
- Novo Nordisk — FDA approves oral semaglutide for cardiovascular risk reduction in adults with type 2 diabetes (SOUL trial, MACE HR 0.86, October 2025).
- Eli Lilly / FDA — Trulicity (REWIND) and Victoza (LEADER) cardiovascular indications; Zepbound prescribing information (no MACE indication as of May 2026).
- Packer M et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT). NEJM, 2025. Eli Lilly — SURPASS-CVOT topline (tirzepatide noninferior to dulaglutide for MACE in type 2 diabetes, July 2025). SURMOUNT-MMO design (results pending).
- FDA — statements on non-FDA-approved compounded GLP-1 drugs. CMS — Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027); Medicare Part D cardiovascular coverage for Wegovy (since August 2024).
- Ro and Sesame Care — weight-loss pricing pages. Pricing verified . Prices and approvals change; we re-verify monthly.
This article is for general information and isn’t medical advice. GLP-1 medications are prescription drugs with real risks and benefits. Talk with a licensed clinician or cardiologist about what’s right for you. Individual results vary.
Related reading
- Wegovy for Heart Disease: full eligibility & coverage guide
- Best GLP-1 for Diabetes: A1C, heart, and kidney comparison
- Best GLP-1 for Fastest Weight Loss 2026
- Best GLP-1 with active savings card 2026 ($25/month rules)
- GLP-1 cost without insurance: complete 2026 guide
- Best GLP-1 telehealth providers in 2026
- Ro Body Reviews (2026): cost, complaints & verdict
- GLP-1 contraindications: who should not start